ETON
Eton Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$49.22
−2.17%Oct 14, 2026, 11:32 UTC
Aquestive Therapeutics agreed to serve as Eton Pharmaceuticals' exclusive manufacturer and supplier of the product under a supply agreement with an initial 20-year term.
Oct 14, 2026, 10:50 UTC
Eton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film.
Source:Sep 28, 2026, 10:50 UTC
Eton Pharmaceuticals launched IMPAVIDO (miltefosine) capsules in the United States.
Source:Aug 13, 2026, 20:05 UTC
Eton Pharmaceuticals reported its financial results for the quarter ended June 30, 2026.
Aug 5, 2026, 10:50 UTC
Eton Pharmaceuticals licensed U.S. rights to late-stage product candidate ASN-001 (timolol topical gel) from Auson Pharmaceuticals, expanding its infantile hemangioma franchise.
Source:Aug 4, 2026, 00:00 UTC
Eton Pharmaceuticals announced the promotion of Danka Radosavljevic to Chief Operating Officer, effective July 31, 2026.
Jul 29, 2026, 10:50 UTC
Eton Pharmaceuticals submitted a Prior Approval Supplement to the FDA to expand the indication of KHINDIVI oral solution to younger pediatric patients.
Source: